Signaturefd LLC Has $356,000 Holdings in Moderna, Inc. (NASDAQ:MRNA)

Signaturefd LLC lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 12.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,581 shares of the company’s stock after selling 502 shares during the quarter. Signaturefd LLC’s holdings in Moderna were worth $356,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Moderna by 0.7% in the third quarter. Vanguard Group Inc. now owns 27,658,449 shares of the company’s stock valued at $2,856,841,000 after buying an additional 196,012 shares during the period. Wellington Management Group LLP lifted its position in shares of Moderna by 9.3% in the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock worth $579,572,000 after purchasing an additional 476,201 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Moderna by 77.3% in the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after purchasing an additional 1,690,341 shares in the last quarter. Invesco Ltd. lifted its position in shares of Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after purchasing an additional 517,683 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Moderna by 1.9% in the third quarter. Northern Trust Corp now owns 2,971,056 shares of the company’s stock worth $306,880,000 after purchasing an additional 55,177 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

NASDAQ:MRNA opened at $106.18 on Friday. Moderna, Inc. has a one year low of $62.55 and a one year high of $142.79. The company has a market cap of $40.65 billion, a P/E ratio of -8.56 and a beta of 1.62. The firm’s fifty day moving average price is $102.15 and its two-hundred day moving average price is $93.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same period in the previous year, the company earned $3.61 earnings per share. The company’s quarterly revenue was down 44.9% on a year-over-year basis. Equities analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The disclosure for this sale can be found here. Insiders have sold a total of 109,954 shares of company stock worth $11,533,976 over the last ninety days. Insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of a number of research reports. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 2nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.